AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have ...
Ginkgo Bioworks (DNA) completed the first milestone of a partnership with Merck (MRK) focused on improving biologic manufacturing. As part of ...
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback